UBS AM
CRBP icon

UBS AM’s Corbus Pharmaceuticals CRBP Stock Holding History

UBS AM’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5K Hold
1,224
– – ﹤0.01% 3241
2026
Q1 		$11.5K Buy
1,224
+285
+30% +$2.4K ﹤0.01% 3278
2025
Q4 		$7.64K Buy
+939
New +$11.6K ﹤0.01% 2904
2020
Q4 		– Sell
-1,707
Closed -$92.2K – 2558
2020
Q3 		$92.2K Buy
1,707
+217
+15% +$39.3K ﹤0.01% 2466
2020
Q2 		$375K Buy
+1,490
New +$301K ﹤0.01% 2224

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

UBS AM's CRBP Position: Q2 2026 in Review

UBS AM held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 1,224 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

UBS AM first reported a position in CRBP in Q2 2020 and has held it in 5 quarters since. The position peaked at $375K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • UBS AM held 1,224 shares of Corbus Pharmaceuticals worth $11.5K as of Q2 2026.
  • UBS AM left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3241 holding.
  • UBS AM first reported a position in Corbus Pharmaceuticals in Q2 2020 and has held it in 5 quarters since.
  • UBS AM's Corbus Pharmaceuticals position peaked at $375K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.